



PTO DOCUMENT PCT 06 FEB 2003

PTO/SB/64 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#11

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED  
UNINTENTIONALLY UNDER 37 CFR 1.137(b)

Docket Number (Optional)

First named inventor: Stefan Masure, et. al.

Application No.: 10/019,337

Art Unit:

Int. No. PCT/EP00/04918

Examiner:

Filed: I.A. March 26, 2000

Title: NEUROTROPHIC FACTOR RECEPTOR

Attention: Office of Petitions  
Assistant Commissioner for Patents  
Box DAC  
Washington, D.C. 20231

NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9282.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus an extensions of time actually obtained.

## APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply and/or issue fee;
- (3) Terminal disclaimer with disclaimer fee –required for all utility and plant applications filed before June 8, 1995; and for all design applications; and
- (4) Statement that the entire delay was unintentional.

## 1. Petition fee

 Small entity-fee \$ \_\_\_\_\_ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27. Other than small entity - fee \$ 1280 (37 CFR 1.17(m))

## 2. Reply and/or fee

A. The reply and/or fee to the above-noted Office action in the form of responses to notice of missing (identify type of reply):  
 has been filed previously on parts & notice of defective response  
 is enclosed herewith. dated 3/6/02 & 6/28/02, respectively

B. The issue fee of \$ \_\_\_\_\_

has been paid previously on \_\_\_\_\_  
 is enclosed herewith.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

- Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.
- A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ \_\_\_\_\_ for a small entity or \$ \_\_\_\_\_ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE. The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D))].

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

January 31, 2003

Date

Telephone  
Number: ( ) 732-524-6932

Myra McCormack

Signature

Myra H. McCormack, Reg. # 36,602

Typed or printed name

Johnson & Johnson/One J&J Plaza

Address

Enclosures:  Fee Payment

New Brunswick, NJ 08933

Reply

Terminal Disclaimer Form

Additional sheets containing statements establishing unintentional delay

Other: \_\_\_\_\_

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box DAC, Washington, D.C. 20231.

transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 308-6916.

January 31, 2003

Date

Myra McCormack

Signature

Myra H. McCormack

Typ or printed name of person signing certificate



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE, et al

Serial No.: 10/019,337 Art Unit: UNKNOWN

I. A. Filed: March 26, 2000 Examiner: UNKNOWN

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on

January 31, 2003

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)

January 31, 2003

(Date of Signature)

Commissioner For Patents  
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME  
AND AUTHORIZATION TO CHARGE  
DEPOSIT ACCOUNT THEREFOR

Dear Sir:


Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Notification of Missing Requirements under 35 USC 371 as dated 6 March 2002. An Amendment responding to the aforesaid Notification is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1512/MHM in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Myra H. McCormack  
Reg. No. 36,602  
Attorney for Applicant(s)

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
DATE: January 31, 2003



DOCKET NO. JAB-1512

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE, et al

Serial No.: 10/019,337 Art Unit: UNKNOWN

I. A. Filed: March 26, 2000 Examiner: UNKNOWN

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on

January 31, 2003

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)

Myra H. McCormack  
(Signature)

January 31, 2003

(Date of Signature)

Commissioner For Patents  
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME  
AND AUTHORIZATION TO CHARGE  
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Notification of Missing Requirements under 35 USC 371 as dated 6 March 2002. An Amendment responding to the aforesaid Notification is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1512/MHM in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Myra H. McCormack  
Myra H. McCormack  
Reg. No. 36,602  
Attorney for Applicant(s)

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
DATE: January 31, 2003



DOCKET NO. JAB-1512

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE, et al

Serial No.: 10/019,337 Art Unit: UNKNOWN

I. A. Filed: March 26, 2000 Examiner: UNKNOWN

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on

January 31, 2003

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)

Myra H. McCormack  
(Signature)

January 31, 2003

(Date of Signature)

Commissioner For Patents  
Washington, D.C. 20231

PETITION FOR EXTENSION OF TIME  
AND AUTHORIZATION TO CHARGE  
DEPOSIT ACCOUNT THEREFOR

Dear Sir:

Applicant(s) petition(s) the Commissioner of Patents and Trademarks to extend the time for response to the Notification of Missing Requirements under 35 USC 371 as dated 6 March 2002. An Amendment responding to the aforesaid Notification is being filed concurrently herewith.

Please charge Deposit Account No. 10-0750/JAB-1512/MHM in the name of Johnson & Johnson for the cost of filing this Petition. Three copies of this Petition are enclosed.

Respectfully submitted,

Myra H. McCormack  
Myra H. McCormack  
Reg. No. 36,602  
Attorney for Applicant(s)

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
DATE: January 31, 2003



Docket No. JAB1512

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Masure, et. al.

Serial No. : 10/019,337 Art Unit: unknown

I.A. Filed : March 26, 2000 Examiner: unknown

For : NEUROTROPHIC FACTOR RECEPTOR

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

**January 31, 2003**

(Date)

**Myra H. McCormack**

Name of applicant, assignee, or Registered Representative

Myra H. McCormack  
(Signature)

**January 31, 2003**

(Date of Signature)

Hon. Commissioner for Patents  
Washington, D.C. 20231

**Response to the Notice to Comply with Sequence Requirements**

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures, Applicants submit the requested sequence together with a Petition for Revival of an Application for Patent Abandoned Unintentionally.

**IN THE SPECIFICATION:**

Kindly delete the existing sequence listing and in the substitute sequence listing provided herewith.

REMARKS

A substitute sequence listing along with a Computer Readable Form of the Sequence Listing is provided herewith. The undersigned hereby states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821 are identical. No new matter has been added by this amendment. A favorable examination of the Application is respectfully requested.

Should the Examiner have any questions he is invited to contact the under signed at the telephone number provided below.

Respectfully submitted,

  
\_\_\_\_\_  
Myra M. McCormack, Ph.D.  
Attorney for Applicants  
Reg. No. 36,602

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
Dated: January 31, 2003



15 JAN 2003

UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

PATENT INFORMATION  
SERVICES

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

JAN 21 2003

49

Myra H. McCormack  
Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003

TO FILE REFER TO

In re Application of  
MASURE, et al.  
U.S. Application No.: 10/019,337  
PCT No.: PCT/EP00/04918  
Int. Filing Date: 26 March 2000  
Priority Date: 29 June 1999  
Attorney Docket No.: JAB-1512  
For: NEUROTROPHIC FACTOR RECEPTOR

COMMUNICATION AND  
NOTIFICATION OF  
ABANDONMENT

This communication is in response to the "Petition For Extension of Time" and "Response to Notification of Defective Response" filed 30 December 2002 in the United States Patent and Trademark Office (USPTO).

#### BACKGROUND

On 26 March 2000, applicant filed international application PCT/EP00/04918, which claimed priority of an earlier application filed 29 June 1999. A Demand for international preliminary examination electing the United States was filed prior to the expiration of nineteen months from the priority date. Accordingly, the thirty-month period for paying the basic national fee in the United States expired at midnight on 29 December 2001.

On 19 December 2001, applicant filed a transmittal letter for entry into the national stage in the United States, which was accompanied by, inter alia: payment of the basic national fee; an executed declaration; an Information Disclosure Statement and a First Preliminary Amendment.

On 06 March 2002, applicant was mailed a "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371" (Form PCT/DO/EO/905) informing applicant of the need to provide a nucleotide and/or amino acid sequence disclosure in compliance with 37 CFR 1.821-1.825. Applicant was afforded two months to file the response.

On 17 April 2002, applicant responded with an amendment to the specification; applicant did not include a computer readable diskette version of the sequence listing.

On 28 June 2002, applicant was mailed a "NOTIFICATION OF DEFECTIVE RESPONSE" (Form PCT/DO/EO/916) informing applicant that the sequence listing filed 17 April 2002 did not comply 37 CFR 1.821-1.825 and thus was not a proper response to the Form PCT/DO/EO/905 mailed 06 March 2002. Applicant was afforded one month from the mailing of the Form PCT/DO/EO/916 or within the time remaining in the response set forth in the Form PCT/DO/EO/905, whichever was longer.

On 30 December 2002, applicant filed the present petition and response considered herein.

### DISCUSSION

The above-identified application was **ABANDONED** on 06 October 2002 for failure to respond to the Form PCT/DO/EO/916 within the time period prescribed therein. Applicant is seeking a five month extension of time from the mail date of the Form PCT/DO/EO/916. However, the only extendable time available was to be calculated from the mail date of the Form PCT/DO/EO/905 mailed 06 March 2002. Thus, the response filed 30 December 2002 is untimely.

### RECOMMENDATION

Applicants may wish to consider filing a petition to the Commissioner under 37 CFR 1.137(a) or (b) requesting that the application be revived. Any petition filed under 37 CFR 1.137(a) and/or a petition under 37 CFR 1.137(b) requesting that the application be revived must meet the criteria indicated in the recent revision of 37 CFR 1.137. See 62 Fed. Reg. 53131 (October 10, 1997); 1203 Off. Gaz. Pat. Office 63 (October 21, 1997) (Effective Date: 01 December 1997).

This recommendation to file a petition under 37 CFR 1.137(a) or (b) should not be construed as an indication as to whether or not any such petition(s) will be favorably considered.

### CONCLUSION

The application is **ABANDONED** as to the United States of America.

This application is being forwarded to the United States Designated/Elected Office (DO/EO/US) for mailing of a "Notification of Abandonment" (Form PCT/DO/EO/909).

Any further correspondence with respect to this matter should be addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231, with the contents of the letter marked to the attention to the PCT Legal Office



Richard Cole  
Legal Examiner  
PCT Legal Office



Derek A. Putonen  
Attorney Advisor  
PCT Legal Office  
Tel: (703) 305-0130  
Fax: (703) 308-6459



## SEQUENCE LISTING

<110> Masure, Stefan  
Cik, Miroslav  
Hoefnagel, Evert

<120> Neurotrophic Factor Receptor

<130> 53202/001

<140> PCT/EP00/04918  
<141> 2000-05-26

<150> GB 9915200.1  
<151> 1999-05-29

<160> 31

<170> PatentIn Ver. 2.0

<210> 1  
<211> 792  
<212> DNA  
<213> Mus musculus

<220>  
<221> misc\_feature  
<222> (583)..(583)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (611)..(611)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (637)..(637)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (664)..(664)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (684)..(684)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (689)..(689)

<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (728)..(728)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (734)..(734)  
<223> n = any amino acid

<220>  
<221> misc\_feature  
<222> (742)..(742)  
<223> n = any amino acid

<400> 1  
gtgcggccgag cgccggcgcc agactttcgc gcccgcctgc gcgttctccg gcccggggtt 60  
ggtgcggccc tcttgccctgg agccccctgga ggcgtgcgag cgcagccgccc tgcgtccgg 120  
cgtgcgtgcg gggcggtcg ggcgcgtcac ccgcgtccgg ggcgcgcgcag gccccgtctc 180  
cttgccttcc aggccctcatg cgctcccgcg cccggctccc ggcgcgcgtcg cccggaggag 240  
gggggcccgc gttgtctgcg cgtctacgca ggcctcatgg gcaccgttgtt caccggaaac 300  
tacctggaca acgtgagcgc ggcgcgttgcg ccctggtgcg gtcgtgcggc cagtggaaac 360  
cggcgcgaaag aatgcgaagc ctccgcgaag ctcttacaa ggaaccgcgtg cttgggtgag 420  
ggggccttgg ggtccccggg aaccacggat gtctgtggcc caatccaagc tgccctggccc 480  
gtgggtctta tttacgtcgc atcatgtttt gtgtggcga tggacaatgt gcacatgcc 540  
tggtagtgg gtggaaatca agcgtaaaaaa cgtgtccaat ggnctggaaag ttggccttcc 600  
ttttgacact natgggggtgg gcctttcttc atgggtngcc caacttacct ttgggtggc 660  
ttgnctctgg gtggaaatgg cttnaattnc agaattttgg gggtcttgg tgaaggctgg 720  
ctttgcnct taanaacttg anaagttaaa ctcttattaa tcccaatggg gttcacctgt 780  
aaaggagag gg 792

<210> 2  
<211> 497  
<212> DNA  
<213> Mus musculus

<400> 2  
gtggAACCGG CGCGAAGAAT GCGAACCTTC CGCAAGCTCT TTACAAGGAA CCCCTGCTTG 60  
gatgggtgcca tacaaggcctt tgacagcttgc cagccatcag ttctgcagga ccagactgct 120  
gggtgtgtt tcccgcgggc aaggcacgag tggcctgaga agagctggag gcagaaaacag 180  
tccttggttt gtcctaacgc ccaagggtgtc ctggctgtat gcactcaactg ccctggctct 240  
ccaggccctg ctctgattag gaacatgaac cgtggacgac acagctgact gccatgtctc 300  
ccgatgactg ctcaactgagc tgaaactccc ttgccttcag gtctgtgtcc ctttgcaggc 360  
ctggaccgcgtgt ctgtggctgt cctctggatt gggggcttgg ggcgtagggtc tgactgaaaa 420  
gcctgtgttc ccgtcagtag gcatcttgc cattttcttc cccatcctag agctgagcac 480  
ccatagatga ggcctca 497

<210> 3  
<211> 901  
<212> DNA  
<213> Rattus rattus

<400>. 3

ggcacccgtgg tcaccccaa ctacctggac aacgtgagcg cgcgcggtgc gcccgtgtc 60  
ggctgtgagg ccagcgaaa coggcgcaag gagtgcaag cttccgcaaa gcttttaca 120  
agaaccct gcttggatgg tgccatacaa gccttgaca gtcgcaacc atcagtctg 180  
caggaccagt ggaacccta ccagaatgct gggtctgtt tcctgtgggt gtctcgatg 240  
tccatactca ctgccctggc tctccaggcc ctgctctaatt taggaaggta aaccatggac 300  
aacacagctg actgccatgt ctctggatta tgctcaactga actgaaaactc cttggccctc 360  
aggtctgtg tcccttgcag ttctggaccc ctgcatggct gtctccttggc ctgggagctg 420  
gaggcttaggg cccgactgtt aggttccctt gtttagtaggc atctcgccctg tttcttac 480  
catcctttag atgatggtag atgatattta gcacctgttag acaggccctc attggggcccc 540  
ttgggcttac agagcagaac agagactagc ctcctgtct tagaattttgg tagtgttctt 600  
ttccaagaag acatggcact aaggcgatca tatgaacaga ctgacagact gcagtctaaa 660  
tacccatgcc ccagggccag cgctgaccctt gcttgcacc tatgacatgg cgctgtgtag 720  
ggattaaaga gagagattca ggtccctctt gctggacatc ccactggcct cccagactct 780  
cccagcacct gcagtggcac agcagctcaa taaacccatg tgcaactgaa aaaaaaaaaa 840  
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagaaaa aaaaaaaaaa 900  
a 901

<210> 4

<211> 872

<212> DNA

<213> Rattus rattus

<400> 4

gtatggggag aggatgtgga gttggcagtt tctcatcggtt cccttctgtt tttacccttc 60  
tcaggcaggg caaggtggag gcctgagtgg cctgagaaga gatggaggca gaaacggtcc 120  
ccgtttgtc ccaaggtgtc ctcgatgtcc atactcaactg ccctggctct ccaggccctg 180  
ctctaattag gaaggtgaac catggacaac acagctgact gccatgtctc tggattatgc 240  
tcactgaact gaaactccct tggccctcagg tctgtgtcc tttgcagttc tggaccctg 300  
catggctgtc tccctggactg ggagctggag gctagggccc gactgttagg ttcccctgtt 360  
agtaggcattc tccctgttt tcttcacccat ctttgagatg atggtagatg atatttagca 420  
cctgttagaca gggccttattt gggccccttg ggcttacaga gcagaacaga gactggccctc 480  
ctgctcttag aattgggttag tggcccttttcaagaagaca tggcactaag gcgtatcatat 540  
gaacagactg acagactgca gtctaaatac ccatggccca gggccagcgc tgacccctgct 600  
tgtcacctat gacatggcgc tggtagggtaaaagagag agattcagttt ccctccctgct 660  
ggacatccca ctggccctccc agactctccc agcacctgca gtggcacagc agctcaataa 720  
accatgtgc actggaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780  
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 840  
aaaaaaaaaa aaaaaagaaa aaaaaaaaaa aa 872

<210> 5

<211> 2522

<212> DNA

<213> Rattus rattus

<400> 5

ctggtaagct ttaaggcaga ggagacctaa gagctgagac atgctatgtt gagtgagcg 60  
tatttacggg tgctgaatga gaggccaggc caggcagttt tatggagttc tggatgccag 120  
agaggttaagg aggtggaaa ggaagtacta taaacctgaa ttgggtgact tggctggatt 180  
tgcatatgtc cagtgccaaag ttccagacata gctgccgggt ttactgtatc tactctccca 240  
aggtcaggca ttctattttc ccctgaatgg ctttcatct gtgacttate tacatcttca 300  
ctgaaactac tggtaaacgt ccaggctgt ctcaggcga agtcctatgg tctgccatta 360  
agccctcagtg tccctgtcagg tgaagctggg gaggatggaa ggggtccagt agacgctctg 420  
tgatgtatgtt gccagttctg gagatgggtgg tggaggctga acctgagttt ctggggaaacc 480  
tccgagttact gcttccattc acgacactggg tggatatccc taggacctgc ccatggccgc 540  
ttcctcagga aaaacgggtc acgcctatgg gccacactct ctcccttgg gttgggtat 600  
ctgccccca ccccccggccaa attccgggggt gtggaatgtg gagaaccaag cacagaggc 660

tgcagcctgc cctccctca ccagggtcag cgagctccac tgagggaaat cgctgcgtgg 720  
 aagcagccga ggcgtgcaca gcagacgagc agtgcgcaga gctgcgtcc gagtacgtgg 780  
 cgcaatgcct gggccggcg ggctggcgaa gaccgggg ctgcgtgcgc tcccgtgcc 840  
 ggcgtccct gcgcgcgttc ttgcgtcccg ggcctccggc gtcacgcac ggcgtgtct 900  
 tctgcggatg cgaaggcccc ggcgtgcgcg agcgcggcg ccagacattc ggcggccct 960  
 ggcgttctc cggcccccag ctggcgccac cttccgtct gaagccctt gaccgctg 1020  
 agcgaagccg cgggtcccg tgctgtcgaa gccggctggg cgcgtcaccg ggcgtccggc 1080  
 ggcgcaggc cccgtctctt tgccctccag gcctcatgcg ctcccgcgc cggctccgc 1140  
 gacggctgtc cggaggaggg gggcccgccg tgcgtgcgc cctacgcagg cttgttaggt 1200  
 acgtggcg gcctctggcg ggcggggcg cggaggcaga ttccggggc cgcgtcacagg 1260  
 tcctgggggt ccctgcaggc accgtggta cccccaacta cctggacaac gtgagcgcgc 1320  
 ggcgtgcgc ctggcgccg tgcgtggcca gcgaaaccg ggcgtcaggag tgcaagcct 1380  
 tccgcaagct ttttacaagg aaccctgtct tgggtgaggg ggctggagag cccggcaac 1440  
 caaggacgtc tatggcccg tctaggctgc ctggcctgtg gggacccta aaatgtttc 1500  
 gtcgtgtcg atttgggtg ggtatggac agtgcacgc tgccatgtg catgggtgg 1560  
 agtcagagga caactgtca gtctcttctt accacgtggg tcccccggat agactggc 1620  
 tcatcgttt tggtgcaag tgccttgcg tgcgtgacca tcttgctggc tgatgtgagc 1680  
 acattttga tggaaagaaa ctgagggttc cagagaccag atagccatc actagagaat 1740  
 tcgagagatg tcaagaatct tctaggctca gaaaggatga gttaaaacat gtccaatgac 1800  
 ctggagttgg ccaaggctcc ctttggcaact actgaggctt tttccctccat gtgtcccaa 1860  
 ttaacgctg ctgttctgc ctggggatga aatagcgtt ttccagattt ctggggggcc 1920  
 gggttgaagc ctgtctctgc cacttcgttag cccagatgtt aactcttatt aatcctaatt 1980  
 gtgttcaccc gtaaggccgg ggtgtgcaact tgcgttgcact actcttagca cagtgacctt 2040  
 ccatctcagg ccgtgccttgc cagattccag ggggtgtctc atttgtctc aaggaggtgg 2100  
 agctgtttctt agggttccct ggccaaacct tctctggatc tctccactcc atagatggt 2160  
 ccatacaagc ctttgcacgc tcgcaaccat cagttctgca ggaccagtgg aaccctacc 2220  
 agaatgctgg gtgctgttc ctgtgggttag gtatggggag aggatgtgga gttggcagtt 2280  
 tctcatcgat ccctctgtt tttacccttc tcaggcaggc caaggtggag gcctgagtg 2340  
 cctgagaaga gatggaggca gaaacggtcc cctttgtc ccaaggtgtc ctgcgtgtcc 2400  
 atactcactg ccctggcttcc ccaaggccctg ctctaattag gaaggtgaac catggacaac 2460  
 acagctgact gccatgttcc tggattatgc tcactgaact gaaactccct tgcctcagg 2520  
 tc  
 2522

<210> 6  
 <211> 953  
 <212> DNA  
 <213> Rattus rattus

<400> 6

ctgttaagct ttaaggcaga ggagacctaa gagctgagac atgctatgtt gagtgagcg 60  
 tatttacggg tgctgaatga gaggccaggc caggcagttt tatggagttc tggatgccag 120  
 agagggtcag cgagctccac tgagggaaat cgctgcgtgg aagcagccga ggcgtgcaca 180  
 gcagacgagc agtgcgcaga gctgcgtcc gatgtcgcc gcaatgcctt gggccggcg 240  
 ggctggcgaa gaccggggag ctgcgtgcgc tcccgtgcc ggcgtgcctt ggcgcgttc 300  
 ttgcggcccg ggcctccggc gtcacgcac ggcgtctct tctgcggatg cgaaggcccc 360  
 ggcgtgcgcg agcgcggcg ccagacattc ggcggccct ggcgttctc cggccccccag 420  
 ctggcgccac ttgcgtgcctt gatggccctt gaccgtgcgc agcgttgcgc cgggtgcgg 480  
 cccgtctctt ttgcgttccaa ggccatgc gtcggccgc cggctcccg cgcggctgt 540  
 cggaggagg gggcccgcg gtgtctgcgc gctacgcag gcctttagg caccgtggc 600  
 aacccttacc acctggacaa cgtgagcgcc cgcgttgcgc cttgtgcgg ctgtgaggcc 660  
 agcggaaacc ggcgtcaga gtcgttgcgc ttccgttccaa ttttacaag gaaaccttgc 720  
 ttggatggtg ccatacaagc ctttgcacgc tcgcaaccat cagttctgca ggaccagtgg 780  
 aacccttacc agaatgctgg gtgctgttc ctgtgggtgt ctcgtatgtc cataactcact 840  
 ggcctggctc tccaggccct gctctaatta ggaaggtgaa ccatggacaa cacagctgac 900  
 tgcgttctt ctggattatgc tcactgaact gaaactccct tgcctcagg gtc 953

<210> 7

<211> 1008  
<212> DNA  
<213> Rattus rattus

<400> 7  
ctggtaagct ttaaggcaga ggagacctaa gagctgagac atgctatgtt gagtgagcg 60  
tatttacggg tgctaatga gaggccaggc caggcagttt tatggagtct tggatgccag 120  
agagggtcag cgagctccac ttaggggaat cgctgcgtgg aagcagccga ggcgtgcaca 180  
gcagacgago agtgcagca gctgcgcctc gactacgtgg cgcaatgcct gggccggcg 240  
ggctggccgg gaccgggag ctgcgtgcgc tcccgctgcc gccgtgcct ggcggcttc 300  
ttcgcggcgc ggcctccggc gtcacgcac ggcgtgcctc tctgcggatg cgaaggcccc 360  
gcgtgcgcgc agcgcggcg ccagacattc gcgcggcct gcgcgttctc cggcccccag 420  
ctggcgccac cttccctgcct gaagcccttg gaccgctgcg agcgaagccg cgggtgcgg 480  
ccccgtctct ttgcctcca ggcctcatgc gctccgcgc cccgctccc cgacggctgt 540  
ccggaggagg ggggcccgcg gtgtctgcgc gcctacgcag gcctttagg accgtggtc 600  
acccccaact acctggacaa cgtgagcgcg cgcgtgcgc cctggcgcgg ctgtgaggcc 660  
agcgaaaacc ggcgcaaga gtgcgaagcc ttccgcaagc ttttacaag gaaccctgc 720  
ttggatggtg ccataacaagc cttgacagc tcgcaaccat cagttctgca ggaccagtgg 780  
aacccctacc agaatgtgg gcaggccaag gtggaggcct gagtggccctg agaagagatg 840  
gaggcagaaa cggccccgt tttgtcccaa ggtgtccctcg atgtccatac tcactgcct 900  
ggctctccag gccctgcct aatttaggaag gtgaaccatg gacaacacag ctgactgcca 960  
tgtctctgga ttatgctcac tgaactgaaa ctcccttgcc ctcaggc 1008

<210> 8  
<211> 273  
<212> PRT  
<213> Rattus rattus

<400> 8  
Met Leu Ser Gly Ala Tyr Leu Arg Val Leu Asn Glu Arg Pro Gly Gln  
1 5 10 15  
  
Ala Val Leu Trp Ser Leu Gly Cys Gln Arg Gly Ser Ala Ser Ser Thr  
20 25 30  
  
Glu Gly Asn Arg Cys Val Glu Ala Ala Glu Ala Cys Thr Ala Asp Glu  
35 40 45  
  
Gln Cys Gln Gln Leu Arg Ser Glu Tyr Val Ala Gln Cys Leu Gly Arg  
50 55 60  
  
Ala Gly Trp Arg Gly Pro Gly Ser Cys Val Arg Ser Arg Cys Arg Arg  
65 70 75 80  
  
Ala Leu Arg Arg Phe Phe Ala Arg Gly Pro Pro Ala Leu Thr His Ala  
85 90 95  
  
Leu Leu Phe Cys Gly Cys Glu Gly Pro Ala Cys Ala Glu Arg Arg Arg  
100 105 110  
  
Gln Thr Phe Ala Pro Ala Cys Ala Phe Ser Gly Pro Gln Leu Ala Pro  
115 120 125  
  
Pro Ser Cys Leu Lys Pro Leu Asp Arg Cys Glu Arg Ser Arg Arg Cys  
130 135 140  
  
Arg Pro Arg Leu Phe Ala Phe Gln Ala Ser Cys Ala Pro Ala Pro Gly

145

150

155

160

Ser Arg Asp Gly Cys Pro Glu Glu Gly Gly Pro Arg Cys Leu Arg Ala  
 165 170 175

Tyr Ala Gly Leu Val Gly Thr Val Val Thr Pro Asn Tyr Leu Asp Asn  
 180 185 190

Val Ser Ala Arg Val Ala Pro Trp Cys Gly Cys Glu Ala Ser Gly Asn  
 195 200 205

Arg Arg Glu Glu Cys Glu Ala Phe Arg Lys Leu Phe Thr Arg Asn Pro  
 210 215 220

Cys Leu Asp Gly Ala Ile Gln Ala Phe Asp Ser Ser Gln Pro Ser Val  
 225 230 235 240

Leu Gln Asp Gln Trp Asn Pro Tyr Gln Asn Ala Gly Cys Cys Phe Leu  
 245 250 255

Trp Val Ser Ser Met Ser Ile Leu Thr Ala Leu Ala Leu Gln Ala Leu  
 260 265 270

Leu

<210> 9

<211> 258

<212> PRT

<213> Rattus rattus

<400> 9

Met Leu Ser Gly Ala Tyr Leu Arg Val Leu Asn Glu Arg Pro Gly Gln  
 1 5 10 15

Ala Val Leu Trp Ser Leu Gly Cys Gln Arg Gly Ser Ala Ser Ser Thr  
 20 25 30

Glu Gly Asn Arg Cys Val Glu Ala Ala Glu Ala Cys Thr Ala Asp Glu  
 35 40 45

Gln Cys Gln Gln Leu Arg Ser Glu Tyr Val Ala Gln Cys Leu Gly Arg  
 50 55 60

Ala Gly Trp Arg Gly Pro Gly Ser Cys Val Arg Ser Arg Cys Arg Arg  
 65 70 75 80

Ala Leu Arg Arg Phe Phe Ala Arg Gly Pro Pro Ala Leu Thr His Ala  
 85 90 95

Leu Leu Phe Cys Gly Cys Glu Gly Pro Ala Cys Ala Glu Arg Arg Arg  
 100 105 110

Gln Thr Phe Ala Pro Ala Cys Ala Phe Ser Gly Pro Gln Leu Ala Pro  
 115 120 125

Pro Ser Cys Leu Lys Pro Leu Asp Arg Cys Glu Arg Ser Arg Arg Cys  
130 135 140

Arg Pro Arg Leu Phe Ala Phe Gln Ala Ser Cys Ala Pro Ala Pro Gly  
145 150 155 160

Ser Arg Asp Gly Cys Pro Glu Glu Gly Gly Pro Arg Cys Leu Arg Ala  
165 170 175

Tyr Ala Gly Leu Val Gly Thr Val Val Thr Pro Asn Tyr Leu Asp Asn  
180 185 190

Val Ser Ala Arg Val Ala Pro Trp Cys Gly Cys Glu Ala Ser Gly Asn  
195 200 205

Arg Arg Glu Glu Cys Glu Ala Phe Arg Lys Leu Phe Thr Arg Asn Pro  
210 215 220

Cys Leu Asp Gly Ala Ile Gln Ala Phe Asp Ser Ser Gln Pro Ser Val  
225 230 235 240

Leu Gln Asp Gln Trp Asn Pro Tyr Gln Asn Ala Gly Gln Ala Lys Val  
245 250 255

Glu Ala

<210> 10

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCT primer

<400> 10

cgcgttgtct ggcgcgtctac g

21

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 11

cggcgccgaag aatgcgaagc

20

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 12

caccacgtac ccatggcatg tgc

23

<210> 13

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 13

tggttcaccc ccaactacct gg

22

<210> 14

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 14

gccttccgca agcttttac aagg

24

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 15

gctttctgc ggatgcgaag gc

22

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 16

agctgccggg tttactgatg ctac

24

<210> 17

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 17

gatgctactc tcccaaggc aggc

24

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 18

ctggtaagct ttaaggcaga ggagacc

27

<210> 19

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 19

catggcagtc agctgtgtt ccc

23

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 20

cagctgtgtt gtccatggtt cacc

24

<210> 21

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 21

tgggtgcgag ctgtcaaagg cttgttatggc

30

<210> 22  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 22  
ggggttcctt gtaaaaaagct tgcggaaggc 30

<210> 23  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 23  
ggtccaaggg cttcaggcag gaagg 25

<210> 24  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 24  
gccttcgcat ccgcagaaga gc 22

<210> 25  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 25  
ccaggttagtt gggggtgacc acg 23

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 26

cccaggcatt gcgccacgta

20

<210> 27  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 27  
cattgcggca cgtactcgga gc

22

<210> 28  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 28  
gacctgaggg caagggagtt tca

23

<210> 29  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 29  
gcaagggagt ttcatgttcag tgagc

25

<210> 30  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 30  
ccatcctaat acgactcact atagggc

27

<210> 31  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 31

actcactata gggctcgagc ggc

23